Preparation method of epigallocatechin gallate alkyl derivative

By using amines and imidazole ionic liquids to catalyze the reaction of (-)EGCG with halogenated alkanes under an inert atmosphere, the alkylation process of (-)EGCG is simplified, and the problems of cumbersome steps and high catalyst cost in the prior art are solved, so as to achieve High-efficiency and low-cost (-)EGCG alkylated derivative preparations.

CN118978506APending Publication Date: 2024-11-19HUNAN CHENGDA BIOLOGICAL TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411069253.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-06
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

In the prior art, the alkylation steps of epigallocate gallate (-)EGCG are complicated and complex in operation, which limits its application in the pharmaceutical field, and has high catalyst costs and harsh reaction conditions.

Method used

Under the protection of an inert atmosphere, the catalysis of amines and imidazoles ionic liquids is used to alkylate (-)EGCG with halogenated alkanes to prepare (-)EGCG alkylated derivatives, which simplifies the reaction steps and reduces the catalyst cost.

Benefits of technology

The (-)EGCG alkylated derivatives were prepared with low cost and high yield in one-step process. The reaction conditions were mild, the operation was simple, and the chemical selectivity was high, making up for the shortcomings of the prior art.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118978506A_ABST
    Figure CN118978506A_ABST
Patent Text Reader

Abstract

The invention discloses a preparation method of an epigallocatechin gallate alkyl derivative, which comprises the following steps: under the protection of inert atmosphere, in the presence of amine and under the catalysis of imidazole ionic liquid, carrying out alkylation reaction on (-) EGCG and halogenated alkane 2 to obtain a (-) EGCG alkylated derivative 3; the structural formula is shown in the description, namely the epigallocatechin gallate alkyl derivative. The method has the following advantages: (1) the catalyst is low in cost, cheap, easy to obtain, green and environment-friendly; (2) the reaction conditions are mild, and the operation is simple; (3) the alkylation reaction has high chemical selectivity and high yield; # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of organic synthesis, and in particular relates to a method for preparing an epigallocatechin gallate alkyl derivative. Background Art

[0002] Epigallocatechin gallate (-) EGCG is the active ingredient of tea polyphenols, which has multiple biological and pharmacological activities such as anti-virus, anti-free radical DNA damage, anti-tumor, hypolipidemic, cardiotonic, anti-atherosclerosis, and anti-angiogenesis. However, (-) EGCG has a high polarity and contains multiple hydroxyl groups in its molecular structure, which results in low fat solubility and bioavailability, which to some extent limits its application in the fields of medicine.

[0003] Alkylation of the hydroxyl groups in (-)EGCG to generate (-)EGCG alkyl derivatives is one of the effective ways to improve its lipid solubility and bioavailability. Currently, the alkylation of (-)EGCG is mainly achieved through protection / deprotection strategies, which have the disadvantages of cumbersome steps and complex operations.

[0004] Ionic liquids (ILs) are composed of larger organic cations and inorganic or organic anions. They have the advantages of good stability, low volatility, easy recycling, environmental protection, and easy structural adjustment. They have important application value in functional materials, extraction and separation, organic synthesis, catalysis and other fields. Summary of the invention

[0005] The technical problem to be solved by the present invention is to overcome the deficiencies and defects mentioned in the above background technology and provide a method for efficiently preparing epigallocatechin gallate alkyl derivatives.

[0006] In order to solve the above technical problems, the technical solution proposed by the present invention is:

[0007] A method for preparing an epigallocatechin gallate alkyl derivative comprises the following steps:

[0008] Under the protection of an inert atmosphere, in the presence of an amine and under the catalysis of an imidazole ionic liquid, (-)EGCG is subjected to an alkylation reaction with a halogenated alkane 2 to obtain a (-)EGCG alkylated derivative 3, namely, the epigallocatechin gallate alkyl derivative;

[0009] The structural formulas of the (-)EGCG, halogenated alkane 2 and (-)EGCG alkylated derivative 3 are as follows:

[0010]

[0011] Where R is C 1~3 Alkyl, X is halogen.

[0012] As a further improvement, R is methyl or ethyl, and X is I.

[0013] As a further improvement, the amine is selected from one or more of diethylamine, N-methylethylamine, diisopropylamine, diisopropylethylamine, N,N'-dimethylethylenediamine, homopiperazine, tetramethylethylenediamine, triphenylamine, diphenylamine, N-methylaniline, dibenzylamine, N-isopropylaniline, N-methyldiphenylamine, 2-phenylaminopyrimidine or dicyclohexylamine.

[0014] As a further improvement, the amine is N,N'-dimethylethylenediamine.

[0015] As a further improvement, the molar amount of the amine added is 1.0 to 3.0 times that of (-)EGCG.

[0016] As a further improvement, the imidazolium ionic liquid catalyst is selected from one or more of the following compounds: 1-butyl-3-methylimidazolium hexafluorophosphate, 1-butyl-3-methylimidazolium phosphate, 1-butyl-3-methylimidazolium dimethyl phosphate, 1-butyl-3-methylimidazolium dihydrogen phosphate, 1-butyl-3-methylimidazolium dibutyl phosphate, 1-butyl-3-methylimidazolium methanesulfonate, 1-butyl-3-methylimidazolium p-toluenesulfonate, 1-butyl-3-methylimidazolium trifluoromethylsulfonate, 1-butyl-3-methylimidazolium nitrate, 1-butyl-3-methylimidazolium perchlorate, 1-butyl-3-methylimidazolium L-proline salt or 1-butyl-3-methylimidazolium hydroxide.

[0017] As a further improvement, the imidazole ionic liquid catalyst is 1-butyl-3-methylimidazolium hexafluorophosphate.

[0018] As a further improvement, the molar addition amount of the imidazole ionic liquid catalyst is 10 to 50% of the raw material (-)EGCG.

[0019] As a further improvement, the reaction solvent of the alkylation reaction is selected from one or more of N-methylpyrrolidone (NMP), THF, DMF, DMSO, chloroform, acetonitrile, acetone, ethanol, isopropanol, methanol, tert-butanol, ether or toluene.

[0020] As a further improvement, the temperature of the alkylation reaction is 60-150°C.

[0021] Compared with the prior art, the present invention has the following beneficial effects:

[0022] The present invention uses imidazole ionic liquid to catalyze the alkylation reaction of (-)EGCG, and efficiently prepares (-)EGCG alkylated derivatives in one step at low cost and high yield, which can make up for the series of deficiencies of the existing protection / deprotection strategy to achieve (-)EGCG alkylation, and has the following advantages: (1) the catalyst cost is low, cheap and easy to obtain, and green and environmentally friendly; (2) the reaction conditions are mild and the operation is simple; (3) the alkylation reaction has high chemical selectivity and high yield. DETAILED DESCRIPTION

[0023] In order to facilitate the understanding of the present invention, the present invention will be described more comprehensively and carefully in combination with preferred embodiments below, but the protection scope of the present invention is not limited to the following specific embodiments.

[0024] Unless otherwise defined, all professional terms used below have the same meanings as those generally understood by those skilled in the art. The professional terms used herein are only for the purpose of describing specific embodiments and are not intended to limit the scope of protection of the present invention.

[0025] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or prepared by existing methods.

[0026] The preparation method of the epigallocatechin gallate alkyl derivative (-)EGCG alkyl derivative of the present invention is that under the protection of an inert atmosphere (such as nitrogen), in the presence of an amine, and under the catalysis of an imidazole ionic liquid, (-)EGCG and a halogenated alkane 2 undergo an alkylation reaction to obtain a (-)EGCG alkylated derivative 3. The reaction path is as follows:

[0027]

[0028] Where R is C 1~3 The alkyl group is preferably a methyl group or an ethyl group.

[0029] X is a halogen, preferably I. Compared with alkyl bromide compounds or chlorine compounds, the CI bond in the alkyl iodide compounds is easier to break, so the alkyl iodide compounds have higher reactivity and better effects.

[0030] In some embodiments, the haloalkane 2 is one of the following compounds:

[0031]

[0032] In some embodiments, the molar ratio of the raw material (-)EGCG to the halogenated alkane 2 is 1:(1-1.5), preferably 1:(1-1.2).

[0033] In some embodiments, the (-)EGCG alkylated derivative 3 is one of the following compounds:

[0034]

[0035] Affected by the electron-withdrawing effect of the ester group, the meta-hydroxyl group on the benzene ring connected to the ester group has the best reaction activity, so the alkylation reaction mainly occurs at the meta-position of the benzene ring connected to the ester group. The present invention can synthesize the target product with high yield by strictly controlling the amount of the reactant halogenated alkane and other reaction conditions. After separation and purification, the pure target product is directly obtained.

[0036] In some embodiments, the amine is one of the following compounds: diethylamine, N-methylethylamine, diisopropylamine, diisopropylethylamine, N,N'-dimethylethylenediamine, homopiperazine, tetramethylethylenediamine, triphenylamine, diphenylamine, N-methylaniline, dibenzylamine, N-isopropylaniline, N-methyldiphenylamine, 2-phenylaminopyrimidine, dicyclohexylamine. N,N'-dimethylethylenediamine is preferred, with the highest yield, and 2-phenylaminopyrimidine is second preferred. The nitrogen atom on the amine can form a hydrogen bond with the hydrogen atom in the hydroxyl group, thereby activating the hydroxyl group and facilitating the reaction.

[0037] In some embodiments, the molar amount of the amine added is 1.0 to 3.0 times that of (-)EGCG.

[0038] In some embodiments, the imidazolium ionic liquid catalyst is the following compound: 1-butyl-3-methylimidazolium hexafluorophosphate, 1-butyl-3-methylimidazolium phosphate ([C4MIm]PO4), 1-butyl-3-methylimidazolium dimethyl phosphate ([C4MIm]POM2), 1-butyl-3-methylimidazolium dihydrogen phosphate ([C4MIm]H2PO4), 1-butyl-3-methylimidazolium dibutyl phosphate ([C4MIm]POB2), 1-butyl-3-methylimidazolium methanesulfonate ([C4MIm]POB ... Im]MS), 1-butyl-3-methylimidazole toluenesulfonate ([C4MIm]TS), 1-butyl-3-methylimidazole trifluoromethylsulfonate ([C4MIm]TfS), 1-butyl-3-methylimidazole nitrate ([C4MIm]NO3), 1-butyl-3-methylimidazole perchlorate ([C4MIm]ClO4), 1-butyl-3-methylimidazole L-proline salt ([C4MIm]L-Pro), 1-butyl-3-methylimidazole hydroxide ([C4MIm]OH). 1-butyl-3-methylimidazole hexafluorophosphate is preferred, with the highest yield.

[0039] In some embodiments, the molar addition amount of the imidazole ionic liquid catalyst is 10-50% of the raw material (-)EGCG.

[0040] In some embodiments, the reaction solvent is one of the following solvents: N-methylpyrrolidone (NMP), THF, DMF, DMSO, chloroform, acetonitrile, acetone, ethanol, isopropanol, methanol, tert-butanol, ether, toluene. Tert-butanol is preferred, with the highest yield, and ethanol is second preferred.

[0041] In some embodiments, the reaction temperature is controlled at 60-150° C., preferably 90-120° C., and the reaction time is 6-20 h.

[0042] In some embodiments, after the reaction is completed, the reaction solvent is dried, a purification solvent is added for slurrying, and crystallization is performed to obtain a pure (-)EGCG alkylated derivative 3. The purification solvent is one of the following: methanol, methanol / H2O, ethanol, ethanol / H2O, tert-butanol, THF, acetone, methanol / THF, ethanol / THF, methanol / ethyl acetate, methanol / acetone. Preferably, ethanol / H2O.

[0043] Example 1

[0044] In a 250mL three-necked flask, raw materials (-)-EGCG (0.4584g, 1.0mmol), iodomethane (0.1703g, 1.2mmol), N,N'-dimethylethylenediamine (0.1322g, 1.5mmol), 1-butyl-3-methylimidazolium hexafluorophosphate (0.0852g, 0.3mmol) and tert-butyl alcohol (5mL) were added. Under nitrogen protection, the reaction was carried out at 80°C for 16h. After the reaction was completed, the solvent was dried, ethanol (20mL) and water (5mL) were added, and the mixture was placed in an ice bath for crystallization overnight to obtain crystals, namely product 3a (0.3401g, 72%).

[0045] The target product 3a has the following structural formula:

[0046]

[0047] The target product is a white solid with a yield of 72% (mol).

[0048] 1 H NMR (400MHz, CD3OD): δ7.06 (s, 2H), 6.98 (s, 2H), 6.51 (d, J = 4.0Hz, 2H), 5.76 ( s,1H),5.47(s,1H),4.93(br,8H),3.83(s,3H),2.96(dd,J=16.5,3.2Hz,1H).

[0049] The above Example 1 was used as the standard reaction condition, and the following comparative experiment was carried out to perform the methylation reaction of (-)-EGCG with iodomethane under different conditions to synthesize 3a. The differences from the standard reaction conditions are listed in the following table (according to the molar amount of each raw material added in Example 1).

[0050]

[0051]

[0052] Example 2

[0053] In a 250mL three-necked flask, raw materials (-)-EGCG (0.4584g, 1.0mmol), iodoethane (0.1872g, 1.2mmol), N,N'-dimethylethylenediamine (0.1322g, 1.5mmol), 1-butyl-3-methylimidazolium hexafluorophosphate (0.0852g, 0.3mmol) and tert-butyl alcohol (5mL) were added. Under nitrogen protection, the reaction was carried out at 80°C for 16h. After the reaction was completed, the solvent was dried, ethanol (20mL) and water (5mL) were added, and the mixture was placed in an ice bath for crystallization overnight to obtain crystals, namely product 3b (0.3405g, 70%).

[0054] The target product 3b has the following structural formula:

[0055]

[0056] The target product is a white solid with a yield of 70%.

[0057] 1 H NMR (400MHz, CD3OD): δ7.05 (s, 2H), 6.99 (s, 2H), 6.54 (d, J = 4.0Hz, 2H), 5.78 (s, 1H), 5.43 (s, 1H), 5.06 (br, 8H), 3.92 (q, J = 4.6Hz, 2H), 2.85 (dd, J = 17.5, 3.4Hz, 1H), 2.63 (t, J = 4.6Hz, 3H).

[0058] The above is only a preferred embodiment of the present invention and does not limit the present invention in any form. Therefore, any simple modification, equivalent change and modification made to the above embodiment according to the technical essence of the present invention without departing from the content of the technical solution of the present invention shall fall within the scope of protection of the technical solution of the present invention.

Claims

1. A method for preparing an epigallocatechin gallate alkyl derivative, characterized in that: The steps include: Under the protection of an inert atmosphere, in the presence of an amine and under the catalysis of an imidazole ionic liquid, (-)EGCG is subjected to an alkylation reaction with a halogenated alkane 2 to obtain a (-)EGCG alkylated derivative 3, namely, the epigallocatechin gallate alkyl derivative; The structural formulas of the (-)EGCG, halogenated alkane 2 and (-)EGCG alkylated derivative 3 are as follows: Where R is C 1~3 Alkyl, X is halogen.

2. The method for preparing the epigallocatechin gallate alkyl derivative according to claim 1, characterized in that: R is methyl or ethyl, and X is I.

3. The method for preparing the epigallocatechin gallate alkyl derivative according to claim 1 or 2, characterized in that: The amine is selected from one or more of diethylamine, N-methylethylamine, diisopropylamine, diisopropylethylamine, N,N'-dimethylethylenediamine, homopiperazine, tetramethylethylenediamine, triphenylamine, diphenylamine, N-methylaniline, dibenzylamine, N-isopropylaniline, N-methyldiphenylamine, 2-phenylaminopyrimidine or dicyclohexylamine.

4. The method for preparing the epigallocatechin gallate alkyl derivative according to claim 3, characterized in that: The amine is N,N'-dimethylethylenediamine.

5. The method for preparing the epigallocatechin gallate alkyl derivative according to claim 3, characterized in that: The molar amount of the amine added is 1.0 to 3.0 times that of (-)EGCG.

6. The method for preparing the epigallocatechin gallate alkyl derivative according to claim 1 or 2, characterized in that: The imidazolium ionic liquid catalyst is selected from one or more of the following compounds: 1-butyl-3-methylimidazolium hexafluorophosphate, 1-butyl-3-methylimidazolium phosphate, 1-butyl-3-methylimidazolium dimethyl phosphate, 1-butyl-3-methylimidazolium dihydrogen phosphate, 1-butyl-3-methylimidazolium dibutyl phosphate, 1-butyl-3-methylimidazolium methanesulfonate, 1-butyl-3-methylimidazolium p-toluenesulfonate, 1-butyl-3-methylimidazolium trifluoromethylsulfonate, 1-butyl-3-methylimidazolium nitrate, 1-butyl-3-methylimidazolium perchlorate, 1-butyl-3-methylimidazolium L-proline salt or 1-butyl-3-methylimidazolium hydroxide.

7. The method for preparing the epigallocatechin gallate alkyl derivative according to claim 6, characterized in that: The imidazole ionic liquid catalyst is 1-butyl-3-methylimidazolium hexafluorophosphate.

8. The method for preparing the epigallocatechin gallate alkyl derivative according to claim 6, characterized in that: The molar addition amount of the imidazole ionic liquid catalyst is 10-50% of the raw material (-)EGCG.

9. The method for preparing the epigallocatechin gallate alkyl derivative according to claim 1 or 2, characterized in that: The reaction solvent of the alkylation reaction is selected from one or more of N-methylpyrrolidone (NMP), THF, DMF, DMSO, chloroform, acetonitrile, acetone, ethanol, isopropanol, methanol, tert-butanol, ether or toluene.

10. The method for preparing epigallocatechin gallate alkyl derivative according to claim 1 or 2, characterized in that: The temperature of the alkylation reaction is 60-150°C.